Chris Ryan

Articles

UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma

March 7th 2024

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma

March 7th 2024

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for select patients with relapsed/refractory follicular lymphoma.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

FDA Awards Orphan Drug Designation to Avutometinib Alone or With Defactinib for Recurrent Low-Grade Serous Ovarian Cancer

March 6th 2024

Avutometinib alone or in combination with defactinib has received an orphan drug from the FDA for recurrent low-grade serous ovarian cancer.

Iopofosine Plus EBRT Produces Remissions, Proves Safe in Recurrent/Metastatic Head and Neck Cancer

March 5th 2024

Iopofosine plus EBRT elicited a 64% CR rate and was well tolerated in patients with locoregionally recurrent/metastatic head and neck cancer.

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

March 5th 2024

The FDA has approved the biosimilars denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti) for use in all indications of the reference medicines denosumab (Xgeva) and denosumab (Prolia).

FDA Lifts Clinical Hold on Trial Investigating LN-145 in NSCLC

March 4th 2024

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

Zevorcabtagene Autoleucel Wins Approval in China for R/R Multiple Myeloma

March 1st 2024

China’s NMPA has approved zevor-cel for the treatment of adult patients with relapsed/refractory multiple myeloma after at least 3 lines of therapy.

HIPEC Elicits Similar Complication Rates, PFS in FIGO Stage III and IV Ovarian Cancer

March 1st 2024

HIPEC was not associated with additional complications or worse survival in patients with FIGO stage IV ovarian cancer vs those with stage III disease.

Retrospective Study Suggests Large Proportion of EU-Approved Oncology Drugs Offer Minimal or No Added Benefit

February 29th 2024

Most oncology drugs approved by the EMA recover research and development costs within a few years, even if the drug is providing little added benefit.

FDA Awards Fast Track Designation to IDP-023 for Non-Hodgkin Lymphoma and Myeloma

February 29th 2024

The FDA has granted fast track designation to IDP-023 for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma

FDA Awards Fast Track Designation to 9MW2821 for Advanced ESCC

February 28th 2024

The FDA granted fast track designation to 9MW2821 for potential use in advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Bezuclastinib Improves Mast Cell Burden, TSS Vs Placebo in Nonadvanced Systemic Mastocytosis

February 27th 2024

Bezuclastinib plus BSC improved mast cell burden and total symptom score vs placebo plus BSC in adult patients with nonadvanced systemic mastocytosis.

FDA Grants Breakthrough Therapy Designation to NVL-520 for Metastatic ROS1+ NSCLC

February 27th 2024

The FDA has granted breakthrough therapy designation to NVL-520 for pretreated, metastatic ROS1-positive non–small cell lung cancer.

FDA Grants Priority Review to sBLA of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

February 27th 2024

The FDA has granted priority review to the sBLA of epcoritamab for relapsed/refractory follicular lymphoma.

A Drive to Help Patients Launches a Career in Revolutionizing Prostate Cancer Care

December 29th 2023

Howard I. Scher, MD, took a passion for improving cancer care and patient outcomes in prostate cancer and turned it into an extraordinary and explosive field of clinical research.

FDA Approves Companion Diagnostic for Capivasertib Plus Fulvestrant in Advanced HR+/HER2–Breast Cancer

November 21st 2023

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.

Bemcentinib Plus SOC Is Well Tolerated, But Does Not Improve Efficacy in Metastatic Melanoma

November 20th 2023

The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.

FDA’s ODAC to Review Data for Ide-Cel in Triple-Class Exposed R/R Myeloma

November 20th 2023

The FDA’s Oncologic Drugs Advisory Committee will meet to review data from the supplemental biologics license application seeking the approval of idecabtagene vicleucel for use in earlier lines of treatment for patients with triple-class exposed relapsed/refractory multiple myeloma.

Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC

November 17th 2023

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.